Theodoros P Vassilakopoulos, Maria Arapaki, Panagiotis T Diamantopoulos, Athanasios Liaskas, Fotios Panitsas, Marina P Siakantaris, Maria Dimou, Styliani I Kokoris, Sotirios Sachanas, Marina Belia, Chrysovalantou Chatzidimitriou, Elianna A Konstantinou, John V Asimakopoulos, Kyriaki Petevi, George Boutsikas, Alexandros Kanellopoulos, Alexia Piperidou, Maria-Ekaterini Lefaki, Angeliki Georgopoulou, Anastasia Kopsaftopoulou, Kalliopi Zerzi, Ioannis Drandakis, Maria N Dimopoulou, Marie-Christine Kyrtsonis, Panayiotis Tsaftaridis, Eleni Plata, Eleni Variamis, Gerassimos Tsourouflis, Flora N Kontopidou, Kostas Konstantopoulos, Gerassimos A Pangalis, Panayiotis Panayiotidis, Maria K Angelopoulou
The significance of serum beta-2 microglobulin (sβ2 m) in Hodgkin lymphoma (HL) is controversial. We analyzed 915 patients with HL, who were treated with ABVD or equivalent regimens with or without radiotherapy. Sβ2 m levels were measured by a radioimmunoassay (upper normal limit 2.4 mg/L). Sequential cutoffs (1.8-3.0 by 0.1 mg/L increments, 3.5 and 4.0 mg/L) were tested along with ROC analysis. The median sβ2 m levels were 2.20 mg/L and were elevated (>2.4 mg/L) in 383/915 patients (41...
January 5, 2024: Cancers